Measuring ROI on a Peptide Program: Margins and Reorders

Most clinics evaluate a peptide program on the wrong number. They look at margin per unit, decide it is healthy, stock a cabinet, and then six months later cannot say whether the program made money. Margin per unit is the easiest number to get and the least informative one in isolation. A product with excellent margin that nobody reorders is a slow-motion write-off. A product with ordinary margin that patients continue for months is a durable revenue line. This article lays out the three numbers that actually determine the return on a peptide program, works an example end to end, and shows why the lever most owners reach for first is the one that moves the result least.

A note on the numbers below. Every figure in the worked example is an illustrative placeholder chosen to make the arithmetic legible, not a representation of anyone's actual pricing or results. Replace them with your own wholesale costs, your own retail prices, and your own observed rates before you make a decision. Results vary by practice, patient mix, and how the program is run.

The Only Three Numbers That Matter

Program return reduces to three inputs, and they multiply rather than add:

• Gross margin per unit. Retail price minus wholesale cost, expressed in dollars and as a percentage.
• Attach rate. The share of clinically appropriate patient conversations that result in a first purchase.
• Reorder rate, or months of continuation. How many units the average patient buys after that first one.

Multiply them out and you get contribution per patient, then contribution per month, then an annual figure you can compare against the working capital and shelf space the program consumes. Owners who track only the first number are measuring a price list. Owners who track all three are measuring a business.

Number One: Gross Margin Per Unit

Start here because it is the input you control most directly and change most rarely. Suppose, purely as an illustration, a wholesale cost of $45 per unit and a retail price of $89. Gross margin is $44 per unit, or roughly 49 percent of the retail price. That single figure tells you the ceiling on everything downstream, but it tells you nothing about whether you will ever reach that ceiling.

Two practical cautions. First, set retail from your market and your service model, not from a multiple someone quoted you. Second, remember that a discount on wholesale cost is a one-time, bounded improvement. Our program includes 10 percent off a first order, no minimums, and volume discounts on larger orders, and those help. They do not change the shape of the program. The variables that do are the two below.

Number Two: Attach Rate

Attach rate is the share of eligible conversations that convert to a first purchase. Eligible means clinically appropriate and actually discussed, not every patient who walks in. This number is usually the one clinics have never measured, and it is usually the one with the most room in it, because it is governed by the consult workflow rather than by anything about the product.

Attach rate is where a program lives or dies in the first ninety days, and the failure mode is almost always operational rather than clinical. We covered the pattern in why peptide programs fail in clinics, and the rollout sequence that avoids it in how to introduce peptides to an existing patient base. If you measure nothing else this quarter, measure how many eligible conversations happened and how many ended in a purchase.

Number Three: Reorder Rate

The third number is the one that compounds. A patient who buys once contributes one unit of margin. A patient who continues for six months contributes six, at no additional acquisition cost. Reorder rate is therefore worth more per point of improvement than anything else on this list, and it is the number most clinics never put on a dashboard.

Two things drive it. The first is expectation setting at the point of the first purchase, which is a communication problem, not a product one. The second is friction, and friction includes the dosage form itself. In a general practice survey of 1,051 patients taking at least one solid oral dosage form, 37.4 percent reported having had difficulty swallowing tablets and capsules; among those affected, 58.8 percent had already modified their medication in ways that can alter safety and efficacy, and 9.4 percent reported non-adherence. The authors also found that general practitioners did not identify 70.4 percent of these patients.¹ Format friction is real, frequently invisible to the prescriber, and it shows up in your reorder line rather than in your chart notes.

This is part of why the delivery route is a business variable and not only a scientific one. Oral absorption of peptides and proteins is limited principally by enzymatic hydrolysis and inadequate permeation into the intestinal mucosa, which is why most peptide therapeutics have historically been delivered parenterally.² Sublingual and buccal administration is a long-established route with roughly seventy-five years of published development behind it, and fast-dissolving films sit among its modern formats.³ Peptides as a therapeutic class are well past novelty: more than eighty peptide drugs have reached the market since insulin.⁴ None of that is a promise about what any individual patient will experience. It is context for why a format that removes a swallowing step is worth measuring against one that does not.

A Worked Example

Take a mid-sized practice, using the illustrative figures above. Assume 60 eligible conversations per month and an attach rate of 20 percent, giving 12 first purchases monthly. Assume the average purchasing patient takes one unit per month and continues for five months.

• Margin per unit: $89 retail minus $45 cost equals $44.
• Units per acquired patient: 5.
• Contribution per acquired patient: 5 units times $44 equals $220.
• Monthly: 12 new patients times $220 equals $2,640 in eventual contribution generated per month.
• Annualized: 144 acquired patients times $220 equals $31,680.

That is the baseline. Now run the sensitivities, because this is where the decision actually gets made.

Why Reorders Beat Discounts

Hold everything else constant and move one input at a time from the baseline above:

• Negotiate 10 percent off wholesale cost ($45 to $40.50). Margin per unit rises to $48.50. Program contribution rises about 10 percent, to roughly $34,920 annually.
• Raise continuation from five months to seven. Contribution per patient rises to $308. Program contribution rises 40 percent, to roughly $44,352 annually.
• Raise attach rate from 20 percent to 30 percent. First purchases rise to 18 per month. Program contribution rises 50 percent, to roughly $47,520 annually.

The purchasing lever is real but bounded; you cannot negotiate your cost below zero. The two behavioral levers are neither bounded in the same way nor dependent on anyone else's cooperation, and each one outperforms the discount by a factor of four or five in this example. The uncomfortable implication for most owners is that the highest-return work on a peptide program is not procurement. It is the consult conversation and the follow-up that happens three weeks after the first purchase.

Return on Inventory Investment

The last piece is the capital the program ties up. The cleanest single metric is annual gross margin divided by average inventory value on hand. Carry the baseline example forward: it moves 720 units a year and produces $31,680 of gross margin. If that practice holds about $3,000 of inventory at cost on average, roughly a month of stock, it is earning something on the order of 10 times its inventory investment per year. That is the number to compare against other uses of the same money and the same cabinet space.

Two failure modes distort it. Overstocking inflates the denominator and buries cash in a cabinet, and it also risks product aging toward its expiration date before it moves. Understocking causes stockouts that quietly kill reorders at exactly the moment continuation is most fragile. The sizing framework for staying between them is in the peptide cabinet inventory math, and the handling routine that protects the inventory you do hold is in storage, shelf life, and handling of oral peptide strips.

What Not to Count

Three things belong outside the ROI calculation. Do not count projected revenue from patients who have not purchased. Do not count clinical outcomes as a financial input; a program's economics and a patient's response are separate questions, and conflating them is how practices talk themselves into recommendations they cannot defend. And do not let the margin on a product influence which patients you consider appropriate for it. The FTC expects health-related claims to be supported by competent and reliable evidence, and the fastest way to end up making unsupported claims is to have a revenue number leaning on the conversation.

Keep the two ledgers separate. Decide clinically who is appropriate, then measure the business honestly on the patients who resulted.

The Monthly Review That Keeps It Honest

This does not require software. Once a month, write down four numbers: eligible conversations, first purchases, repeat purchases, and units on hand. Attach rate is the second divided by the first. Reorder health is the third compared with prior months. Everything in this article is computable from those four figures plus your price list, in about ten minutes. Programs that get reviewed monthly get corrected while correction is still cheap. Programs that get reviewed annually get abandoned.

The Bottom Line for Practices

Margin per unit sets the ceiling. Attach rate and reorder rate determine how much of that ceiling you ever reach, and they are worth several times more attention than the purchasing discount most owners chase first. Measure all three, review them monthly, keep the clinical and financial ledgers separate, and a peptide program becomes a line you can actually manage rather than a cabinet you hope pays for itself.

If you want to run these numbers against real wholesale pricing before you commit shelf space, our team can walk you through the price list and the products that fit your patient mix. Apply for a free wholesale account.

References

1. Schiele JT, Quinzler R, Klimm HD, Pruszydlo MG, Haefeli WE. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2013;69(4):937-948. PubMed: 23052416
2. Mehrotra S, Kalyan BG P, Nayak PG, Joseph A, Manikkath J. Recent progress in the oral delivery of therapeutic peptides and proteins: overview of pharmaceutical strategies to overcome absorption hurdles. Adv Pharm Bull. 2024;14(1):11-33. PubMed: 38585454
3. Bahraminejad S, Almoazen H. Sublingual and buccal delivery: a historical and scientific prescriptive. Pharmaceutics. 2025;17(8):1073. PubMed: 40871092
4. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. PubMed: 33536635

Disclaimer: This article is for educational purposes for healthcare providers and is not medical, legal, tax, or financial advice. Statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease, and they are not FDA-approved. All prices, costs, rates, and dollar figures in this article are illustrative placeholders used to demonstrate a calculation; they are not quotes, projections, or representations of actual pricing or results, and no financial outcome is promised or guaranteed. Results vary by practice. Providers are responsible for their own pricing, recordkeeping, tax treatment, and for operating within their scope of practice and applicable laws.